The Alzheimer's comorbidity phenome: mining from a large patient database and phenome-driven genetics prediction. Issue 1 (19th December 2018)

• Record Type: Journal Article
• Authors: Zheng, Chunlei; Xu, Rong
• Is Part Of: JAMIA open. Volume 2:Issue 1(2019)
• Page Start: 131
• Page End: 138
• Publication Date: 2018-12-19
• Subjects: Alzheimer's disease -- FAERS -- disease comorbidity network -- protein–protein interaction -- disease gene discovery; Medical informatics -- Periodicals; 610.285
• DOI: 10.1093/jamiaopen/ooy050
• Languages: English
• ISSNs: 2574-2531

Abstract

Abstract: Objective: Alzheimer's disease (AD) is a severe neurodegenerative disorder and has become a global public health problem. Intensive research has been conducted for AD. But the pathophysiology of AD is still not elucidated. Disease comorbidity often associates diseases with overlapping patterns of genetic markers. This may inform a common etiology and suggest essential protein targets. US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) collects large-scale postmarketing surveillance data that provide a unique opportunity to investigate disease co-occurrence pattern. We aim to construct a heterogeneous network that integrates disease comorbidity network (DCN) from FAERS with protein–protein interaction (PPI) to prioritize the AD risk genes using network-based ranking algorithm. Materials and Methods: We built a DCN based on indication data from FAERS using association rule mining. DCN was further integrated with PPI network. We used random walk with restart ranking algorithm to prioritize AD risk genes. Results: We evaluated the performance of our approach using AD risk genes curated from genetic association studies. Our approach achieved an area under a receiver operating characteristic curve of 0.770. Top 500 ranked genes achieved 5.53-fold enrichment for known AD risk genes as compared to random expectation. Pathway enrichment analysis using top-ranked genes revealed that two novel pathways, ERBB and coagulation pathways, might be involved in AD pathogenesis. Conclusion: We innovatively leveraged FAERS, a comprehensive data resource for FDA postmarket drug safety surveillance, for large-scale AD comorbidity mining. This exploratory study demonstrated the potential of disease-comorbidities mining from FAERS in AD genetics discovery.